Product
Standard lymphodepletion regimen
Aliases
Cyclophosphamide, Fludarabine
5 clinical trials
5 indications
Indication
Myasthenia GravisIndication
Lupus NephritisIndication
Multiple SclerosisIndication
Primary ProgressiveIndication
Secondary ProgressiveClinical trial
A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, in Subjects With Refractory Generalized Myasthenia Gravis (KYSA-6)Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisStatus: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-1)Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple SclerosisStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)Status: Not yet recruiting, Estimated PCD: 2027-04-01